ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Spondyloarthropathies"

  • Abstract Number: 0575 • ACR Convergence 2024

    Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA

    Kurt de Vlam1, Pieter Ruytinx2, Elien luyten2, Anouk Agten2, Frank Vandenabeele2 and Veerle somers2, 1Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, 2Universiteit Hasselt, Hasselt, Belgium

    Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
  • Abstract Number: 1482 • ACR Convergence 2024

    Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial

    Atul Deodhar1, Eva Dokoupilova2, Cynthia Vizcaya3, Reema Sutariya4, Weibin Bao4, Karen Kapur3, Susanne Rohrer3 and Alan Kivitz5, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
  • Abstract Number: 0078 • ACR Convergence 2024

    Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity

    Archita Srinath1, Daniele Mauro2, Mariia Korshko3, Shaghayegh Foroozan4, Mansi Aparnathi5, Francesco Ciccia6 and Nigil Haroon7, 1University of Toronto, Toronto, ON, Canada, 2University of Campania, Italy, Naples, Naples, Italy, 3University Health Network, Toronto, ON, Canada, 4University Health Network/University of Toronto, Toronto, ON, Canada, 5University Health Network, Toronto, Canada, 6University of Campania, Naples, Italy, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do…
  • Abstract Number: 0589 • ACR Convergence 2024

    Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials

    Laura Coates1, Iain McInnes2, M. Elaine Husni3, Cynthia Vizcaya4, Weibin Bao5 and Philip Mease6, 1University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 2University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 3Cleveland Clinic, Cleveland, OH, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…
  • Abstract Number: 1707 • ACR Convergence 2024

    TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease

    Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
  • Abstract Number: 0082 • ACR Convergence 2024

    Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis

    Mark Harland1, Paula David2, Chi Wong1, Jake Weddell1, Abhay Rao3, Almas Khan3, Jake Timothy3, Peter Loughenbury3, Robert Dunsmuir3, Vishal Borse3, Campbell MacEachern3, Antonius Pieter Van der Heuvel4, Warner Chen4, Tom Macleod1 and Dennis McGonagle5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, 2Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, 5National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom

    Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked…
  • Abstract Number: 0590 • ACR Convergence 2024

    Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials

    Sofia Ramiro1, Corine Gaillez2, Uta Kiltz3, Lianne S Gensler4, Chaitali Pisal5, Juergen Braun6 and Alexis Ogdie7, 1Leiden University Medical Center, Bunde, Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Novartis Healthcare Private Limited, Hyderabad, India, 6Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
  • Abstract Number: 1760 • ACR Convergence 2024

    A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis

    Walter Maksymowych1, Robert Lambert1, Paula Śliwinska-Stańczyk2, Piotr Adrian Klimiuk3, Anusha Yeshokumar4, Elizabeth Cerullo4, Rebecca Kepich4, Chahin Pachai4 and Steven Greenberg4, 1University of Alberta, Edmonton, AB, Canada, 2Centrum Medyczne ReumaPark, Warsaw, Poland, 3Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, 4Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: CC-99677 (also known as BMS-986371) is a novel, orally bioavailable, small-molecule covalent inhibitor of mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MK2). The MK2…
  • Abstract Number: 0141 • ACR Convergence 2024

    The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients

    Melody Esmaeili1, Linh Truong2, Nicole Ridolfi3, Eugenia Chen4 and Maida wong5, 1University of California, Irvine, Orange, CA, 2University of California, Los Angeles, Los Angeles, CA, 3University of California, Irvine, Newport Beach, CA, 4Long Beach VA Hospital, Irvine, CA, 5Long Beach VA Hospital, Los Angeles, CA

    Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
  • Abstract Number: 0604 • ACR Convergence 2024

    Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024

    Mahum Mirza1, Jean Liew2, Michael Putman3 and Shikha Singla1, 1Medical College of Wisconsin, Milwaukee, WI, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
  • Abstract Number: 1850 • ACR Convergence 2024

    Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients

    Samuel Bitoun1, Marie Naigeon2, Matthieu Roulleaux- Dugage2, Caroline De Oliveira2, Caroline Berthot2, Xavier Mariette3, Gaetane Nocturne3 and Nathalie Chaput-Gras2, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, 3Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
  • Abstract Number: 0530 • ACR Convergence 2023

    Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial

    Jeffrey Curtis1, Rebecca Grainger2, Dan Webster3, Jie Shen4, Ana Biljan5, Anna Shmagel4, Peter Wung4 and Philip J. Mease6, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Otago, Wellington, New Zealand, 3AbbVie, Inc., Libertyville, IL, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Buffalo Grove, IL, 6Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Physical activity is associated with reduced pain, improved mobility and physical function in people with ankylosing spondylitis (AS) and plays a crucial role in…
  • Abstract Number: 1689 • ACR Convergence 2023

    Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy

    Lihi Eder1, Xianwei Li2, Sydney Thib3, Darshini Ganatra4, Liqun Diao2 and Vinod Chandran5, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 3Women’s College Research Institute, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: To characterize the relationships between peripheral blood immune cell profiles in patients with psoriatic arthritis (PsA) and (1) baseline clinical and imaging disease features;…
  • Abstract Number: 0539 • ACR Convergence 2023

    Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis

    Maxime Dougados1, David Bulbin2, Heather Jones3, Tianming Gao4, Anna Shmagel5, Thomas Poznanski6, Abhijeet Danve7 and Karl Gaffney8, 1Université de Paris, Paris, France, 2Geisinger Health System, Danville, PA, 3AbbVie, Inc., Mettawa, IL, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Long Grove, IL, 6AbbVie, Inc., Plainfield, IL, 7Yale University, New Haven, CT, 8Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom

    Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…
  • Abstract Number: 1815 • ACR Convergence 2023

    The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register

    Preeti Dhanasekaran1, Margaret Ma2, Manjari Lahiri2, Li Wearn Koh3, Stanley Angkodjojo4, Andrew Yu Keat Khor5, James Jiaqi Liu6, Stephanie Wong7 and Siaw Ing Yeo6, 1National University of Singapore, Singapore, Singapore, 2National University Hospital, Singapore, Singapore, 3Tan Tock Seng Hospital, Braddell Heights, Singapore, 4Sengkang General Hospital / Singhealth, Singapore, Singapore, 5Changi General Hospital, Singapore, Singapore, 6Singapore General Hospital, Singapore, Singapore, 7Tan Tock Seng Hospital, Singapore, Singapore

    Background/Purpose: To determine the association of body mass index (BMI) with incident COVID-19 infection in patients with inflammatory arthritis (IA) using biologic disease-modifying anti-rheumatic drugs…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology